RECENTLY PUBLISHED ISSUES – BENTHAM SCIENCE JOURNALS

Current Vascular Pharmacology Volume 16, Issue 2
http://bit.ly/2FCEQBr

Mini-Reviews in Organic Chemistry Volume 15, Issue 1
http://bit.ly/2EmimVN

Current Pharmaceutical Design Volume 23, Issue 35
http://bit.ly/2Ezc5WV

Current Pharmaceutical Design Volume 23, Issue 36
http://bit.ly/2nBrGwX

Current Medicinal Chemistry Volume 25, Issue 3
http://bit.ly/2nzZQ4o

recent-issues

 

TESTIMONIAL BY RAJEEV K. SINGLA!

Rajeev K. Singla

Contributed Article: “Diabetes Mellitus and Male Aging: Pharmacotherapeutics and Clinical Implications

New Issue :: Current Pharmaceutical Design Volume 23, Issue 34

Current Pharmaceutical Design publishes timely in-depth reviews and research articles from leading pharmaceutical researchers in the field, covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area guest edited by an acknowledged authority in the field.

Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design including: medicinal chemistry, pharmacology, drug targets and disease mechanism.

cpd-14-16

Articles from the journal Combinatorial Chemistry & High Throughput Screening Volume 20, Issue 9

                          For details on the articles, please visit this link :: http://bit.ly/2n9HAyC

RECENTLY PUBLISHED ISSUES – BENTHAM SCIENCE JOURNALS

Protein & Peptide Letters 24-11

http://bit.ly/2DeaIfs

Mini-Reviews in Medicinal Chemistry 18-2

http://bit.ly/2qRzOOI

Mini-Reviews in Medicinal Chemistry 18-3

http://bit.ly/2CMj5Ov

Innovations in Corrosion and Materials Science 7-2

http://bit.ly/2mmdwQp

Current Pharmaceutical Design 23-33

http://bit.ly/2qPs6oo

recent-issues

RECENTLY PUBLISHED ISSUES – BENTHAM SCIENCE JOURNALS

Current Psychiatry Reviews13-3

http://bit.ly/2BsgWHK

Anti-Cancer Agents in Medicinal Chemistry 17-11

http://bit.ly/2B9JYyY

Current Medicinal Chemistry 24 -36

http://bit.ly/2CWxoR8

Current Organic Chemistry 21-23

http://bit.ly/2oAC1Nr

Current Organic Synthesis 14 -7

http://bit.ly/2CTfgr8

Current Pharmaceutical Design 23-30

http://bit.ly/2oAUXvo

Current Drug Targets  18-16

http://bit.ly/2jbzp3c

Current Medicinal Chemistry 24 -37

http://bit.ly/2CUDmSr

Current Genomics 19 -1

http://bit.ly/2BaL5hR

Current Pharmaceutical Design 23 -31

http://bit.ly/2ARCYm4

recent-issues

RECENTLY PUBLISHED ISSUES – BENTHAM SCIENCE JOURNALS

Recent Patents on Drug Delivery & Formulation 11-2

http://bit.ly/2lojMGi

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 16-2

http://bit.ly/2loocwQ

Current Medicinal Chemistry 24-39

http://bit.ly/2E8r5KN

Current Pharmaceutical Design 23-32

http://bit.ly/2CgJUNz

Current Nanoscience 14-1

http://bit.ly/2lpc0fj

Recent Patents on Biotechnology 12-1

http://bit.ly/2DudNam

 recent-issues

RECENTLY PUBLISHED ISSUES – BENTHAM SCIENCE JOURNALS

Current Pharmaceutical Biotechnology 18-8

http://bit.ly/2zjUmBQ

Current Biotechnology 6-4

http://bit.ly/2B7X2EZ

Current Neuropharmacology 15-8

http://bit.ly/2BB1nAd

Current Cancer Therapy Reviews 13-2

http://bit.ly/2kIQDp0

Current Pharmaceutical Design 23-29

http://bit.ly/2BFwmLq

Mini-Reviews in Organic Chemistry 14-6

http://bit.ly/2CyKMKf

Current Organic Chemistry 21-22

http://bit.ly/2ySgZcR

Current Medical Imaging Reviews 13-4

http://bit.ly/2B7l0jP

Current Proteomics 14-4

http://bit.ly/2BahSU8

Endocrine, Metabolic & Immune Disorders – Drug Targets 17-4

http://bit.ly/2AUG8W8

recent-issues

PRESS RELEASE – 2-hydroxypropyl-β-cyclodextrins and blood-brain barrier in Niemann-Pick Disease type C1

This article by Dr. Pericles Calias is published in Current Pharmaceutical Design, Volume 23 , 2017

A new data review concludes that 2-hydroxypropyl-β-cyclodextrin (HPβCD) does not cross the blood-brain barrier (BBB) in therapeutically relevant amounts to address the neurological manifestations of Niemann-Pick Disease Type C1 (NPC1). These manifestations vary with age of onset and include delay in developmental motor milestones, gait problems, falls, clumsiness, vertical supranuclear gaze palsy, cerebellar ataxia, dysarthria, dysphagia and progressive dementia . Based upon physicochemical properties, findings in animal models, early clinical studies, and patient case reports, the evidence to date suggests that HPβCD does not cross the BBB in therapeutically relevant amounts in the NPC1 setting. Direct administration to the central nervous system (CNS) would be expected to provide the greatest NPC1 neurological efficacy and is supported by a phase 1/2a clinical study .

The review was published online in the latest issue of Current Pharmaceutical Design.

NPC1 is an autosomal-recessive, rare lysosomal storage characterized by progressively debilitating and ultimately fatal neurological manifestations. Clinical trials of different HPβCD agents are currently underway and the route of administration is an important point of consideration for the anticipated results of these trials with regard to safety, tolerability and efficacy in the NPC1 population.

Cyclodextrins are complex mixtures of different chemical species and different cyclodextrin products are therefore not the same as one another. When administering drugs directly to the CNS, it is important that the agent being administered is highly purified and well characterized to avoid introducing any contaminants and/or unknown agents that could adversely affect neurological development and/or function. Currently, VTS-270 is the only specific and well-characterized mixture of HPβCD, with a tightly controlled molar substitution specification and a defined molecular “fingerprint” of the different chemical species present in the mixture based on Kleptose® HPB (Roquette Pharma, France).

 

The article is open access and its full text can be downloaded from here: http://www.eurekaselect.com/156484

RECENTLY PUBLISHED ISSUES – BENTHAM SCIENCE JOURNALS

Recent Patents on Mechanical Engineering 10-3

http://bit.ly/2knILJ8

Letters in Drug Design & Discovery 14-12

http://bit.ly/2l1EsHw

Current Topics in Medicinal Chemistry 17-27

http://bit.ly/2B68pw9

Recent Innovations in Chemical Engineering 10-1

http://bit.ly/2B8ffRD

Current Stem Cell Research & Therapy 12-8

http://bit.ly/2yhlgGF

Current Organic Chemistry 21-21

http://bit.ly/2Adezr0

Current Pharmaceutical Design 23-28

http://bit.ly/2yhksS3

Letters in Organic Chemistry 14-10

http://bit.ly/2Aw82vy

recent-issues

HIGHLIGHTED ARTICLE – TARGETING HUMAN ASTROCYTES’ CALCIUM-SENSING RECEPTORS FOR TREATMENT OF ALZHEIMER’S DISEASE – CURRENT PHARMACEUTICAL DESIGN

CPD-23-46-Ubaldo Armato

To access the article, please visit: http://www.eurekaselect.com/154081